9x8: Destro

T-cell activation through "immunogenic cell death" to overcome traditional resistance to immunotherapy in MSS (microsatellite stable) colorectal cancer. 3.

Combining chemotherapy with ICIs like nivolumab aims to convert "cold" tumors (non-responsive) into "hot" tumors (immune-active). Destro 9x8

Preliminary studies, such as the MEDITREME trial (a related study), showed promising early efficacy, with a six-month progression-free survival rate of 62.5%. Preliminary studies, such as the MEDITREME trial (a

Based on the available search results, the "Destro 9x8" appears to refer to the , an ongoing clinical study in metastatic colorectal cancer (mCRC), often discussed in literature regarding immuno-oncology. Report: CheckMate 9X8 Trial Overview 1. Subject Subject The final results of the CheckMate 9X8

The final results of the CheckMate 9X8 trial are expected to validate whether this immunotherapy combination provides a superior progression-free survival (PFS) or overall survival (OS) compared to standard chemotherapy alone.